Walk Ahead for a Brain Tumor Cure on Oct. 21
Thousands expected at annual event
Event Information (passed)
The ninth annual Walk Ahead for a Brain Tumor Cure is Sunday, Oct. 21, 2018 at Sawyer Point.
- Registration begins at 7:30 a.m.
- Timed 5K run begins at 8:30 a.m.
- 5K walk begins at 9 a.m.
- Wheelchair friendly 2K begins at 9 a.m.
Thousands of walkers and runners will support research and educational efforts of the University of Cincinnati Brain Tumor Center at the University of Cincinnati Gardner Neuroscience Institute.
Now nearly a decade in existence, Walk Ahead 2018 will have raised $2 million over its entire lifetime, following the 2018 event.
Brain tumors are not uncommon. More than 200,000 people are stricken with brain tumors in America every year. During the last two decades, the frequency of brain tumors has increased 22 percent overall and 55 percent in people over 65 years of age. The University of Cincinnati Brain Tumor Center is a regional destination for brain tumor patients, providing compassionate care while striving to find causes and cures. The funds raised through Walk Ahead advance the innovative research necessary to developing new treatments.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.